BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 7987386)

  • 1. Parental origin of WT1 mutations and mental retardation in WAGR syndrome.
    Huff V
    Nat Genet; 1994 Sep; 8(1):13-4. PubMed ID: 7987386
    [No Abstract]   [Full Text] [Related]  

  • 2. Familial Wilms' tumor associated with a WT1 zinc finger mutation.
    Kaplinsky C; Ghahremani M; Frishberg Y; Rechavi G; Pelletier J
    Genomics; 1996 Dec; 38(3):451-3. PubMed ID: 8975729
    [No Abstract]   [Full Text] [Related]  

  • 3. A clinical overview of WT1 gene mutations.
    Little M; Wells C
    Hum Mutat; 1997; 9(3):209-25. PubMed ID: 9090524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular genetics of Wilms tumor.
    Grundy P; Coppes MJ; Haber D
    Hematol Oncol Clin North Am; 1995 Dec; 9(6):1201-15. PubMed ID: 8591961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered trans-activational properties of a mutated WT1 gene product in a WAGR-associated Wilms' tumor.
    Park S; Tomlinson G; Nisen P; Haber DA
    Cancer Res; 1993 Oct; 53(20):4757-60. PubMed ID: 8402654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of 11p14-p12 deletion in WAGR syndrome by array CGH for identifying genes contributing to mental retardation and autism.
    Xu S; Han JC; Morales A; Menzie CM; Williams K; Fan YS
    Cytogenet Genome Res; 2008; 122(2):181-7. PubMed ID: 19096215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infrequent mutation of the WT1 gene in 77 Wilms' Tumors.
    Gessler M; König A; Arden K; Grundy P; Orkin S; Sallan S; Peters C; Ruyle S; Mandell J; Li F
    Hum Mutat; 1994; 3(3):212-22. PubMed ID: 8019557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of Wilms' tumor genes.
    Hirose M
    J Med Invest; 1999 Aug; 46(3-4):130-40. PubMed ID: 10687307
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of 11q loss, trisomy 12, and possible 16q loss with loss of imprinting of insulin-like growth factor-II in Wilms tumor.
    Watanabe N; Nakadate H; Haruta M; Sugawara W; Sasaki F; Tsunematsu Y; Kikuta A; Fukuzawa M; Okita H; Hata J; Soejima H; Kaneko Y
    Genes Chromosomes Cancer; 2006 Jun; 45(6):592-601. PubMed ID: 16518847
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Frequency and heritability of WT1 mutations in nonsyndromic Wilms' tumor patients: a UK Children's Cancer Study Group Study.
    Little SE; Hanks SP; King-Underwood L; Jones C; Rapley EA; Rahman N; Pritchard-Jones K
    J Clin Oncol; 2004 Oct; 22(20):4140-6. PubMed ID: 15483024
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Genomic imprinting and human pathology. 2].
    Cirillo Silengo M; Lerone M; Guala A
    Pediatr Med Chir; 1995; 17(5):389-94. PubMed ID: 8684991
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Germline WT1 mutations in Wilms' tumor patients: preliminary results.
    Li FP; Breslow NE; Morgan JM; Ghahremani M; Miller GA; Grundy PE; Green DM; Diller LR; Pelletier J
    Med Pediatr Oncol; 1996 Nov; 27(5):404-7. PubMed ID: 8827066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The same mutation affecting the splicing of WT1 gene is present on Frasier syndrome patients with or without Wilms' tumor.
    Barbosa AS; Hadjiathanasiou CG; Theodoridis C; Papathanasiou A; Tar A; Merksz M; Györvári B; Sultan C; Dumas R; Jaubert F; Niaudet P; Moreira-Filho CA; Cotinot C; Fellous M
    Hum Mutat; 1999; 13(2):146-53. PubMed ID: 10094551
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genomic imprinting at the WT1 gene involves a novel coding transcript (AWT1) that shows deregulation in Wilms' tumours.
    Dallosso AR; Hancock AL; Brown KW; Williams AC; Jackson S; Malik K
    Hum Mol Genet; 2004 Feb; 13(4):405-15. PubMed ID: 14681303
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inactivation of WT1 in nephrogenic rests, genetic precursors to Wilms' tumour.
    Park S; Bernard A; Bove KE; Sens DA; Hazen-Martin DJ; Garvin AJ; Haber DA
    Nat Genet; 1993 Dec; 5(4):363-7. PubMed ID: 8298644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Denys-Drash syndrome point mutations on the DNA binding activity of the Wilms' tumor suppressor protein WT1.
    Borel F; Barilla KC; Hamilton TB; Iskandar M; Romaniuk PJ
    Biochemistry; 1996 Sep; 35(37):12070-6. PubMed ID: 8810912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular biology of Wilms' tumor.
    Koo HP; Hensle TW
    Urol Clin North Am; 1993 May; 20(2):323-31. PubMed ID: 8388135
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Why is the oncogene WT1 in the developing kidney and what is it doing there?
    Chesney RW
    Pediatr Nephrol; 2002 Dec; 17(12):990-2. PubMed ID: 12520325
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical relevance of mutations in the Wilms tumor suppressor 1 gene WT1 and the cadherin-associated protein beta1 gene CTNNB1 for patients with Wilms tumors: results of long-term surveillance of 71 patients from International Society of Pediatric Oncology Study 9/Society for Pediatric Oncology.
    Royer-Pokora B; Weirich A; Schumacher V; Uschkereit C; Beier M; Leuschner I; Graf N; Autschbach F; Schneider D; von Harrach M
    Cancer; 2008 Sep; 113(5):1080-9. PubMed ID: 18618575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotype/phenotype correlations in Wilms' tumor.
    Huff V
    Med Pediatr Oncol; 1996 Nov; 27(5):408-14. PubMed ID: 8827067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.